NCT04939571 European Disease Registry on Retinopathy of Prematurity (ROP)
| NCT ID | NCT04939571 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medicine Greifswald |
| Condition | Retinopathy of Prematurity |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2021-08-06 |
| Primary Completion | 2038-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2021-08-06 with a primary completion date of 2038-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The EU-ROP registry is a European wide multicenter non-interventional observational registry study intended to run open-ended in as many countries as possible including infants treated for retinopathy of prematurity irrespective of the used treatment modality. The registry is strictly observational; only clinical routine data is collected, no study-specific examinations or interventions are to be performed. The aim of the EU-ROP registry is to collect information on as many patients as possible treated for ROP in Europe. Both the number of study centers as well as the number of patients to be included into the registry are not limited. The primary objective is to describe the typical clinical features of infants with severe ROP, variations in phenotype, and the clinical progression of the disease over time (natural history) in different European countries as well as to study treatment patterns, follow-up patterns, as well as long-term outcomes.
Eligibility Criteria
Inclusion Criteria: * ROP requiring treatment according to the respective national ROP screening and treatment guidelines Exclusion Criteria: * Denial or absence of consent for documentation and electronic storage of personal data by parents or legal guardians
Contact & Investigator
Andreas Stahl, Professor
PRINCIPAL INVESTIGATOR
Department of Ophthalmology, University Medicine Greifswald
Frequently Asked Questions
Who can join the NCT04939571 clinical trial?
This trial is open to participants of all sexes, studying Retinopathy of Prematurity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04939571 currently recruiting?
Yes, NCT04939571 is actively recruiting participants. Contact the research team at andreas.stahl@med.uni-greifswald.de for enrollment information.
Where is the NCT04939571 trial being conducted?
This trial is being conducted at Salzburg, Austria, Plovdiv, Bulgaria, Sofia, Bulgaria, Sofia, Bulgaria and 11 additional locations.
Who is sponsoring the NCT04939571 clinical trial?
NCT04939571 is sponsored by University Medicine Greifswald. The principal investigator is Andreas Stahl, Professor at Department of Ophthalmology, University Medicine Greifswald. The trial plans to enroll 3,000 participants.